abdominal painIncreased riskOR=3.21
In Group S, the chance of developing symptoms of ... abdominal pain (OR=3.21) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluanxietyIncreased riskOR=3.58
In Group S, the chance of developing symptoms of ... anxiety (OR=3.58) was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilludiarrheaIncreased riskOR=3.01
In Group S, the chance of developing symptoms of ... diarrhea (OR=3.01) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluheadacheIncreased riskOR=10.51
In Group S, the chance of developing symptoms of ... headache (OR=10.51) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacillunauseaIncreased riskOR=2.74
In Group S, the chance of developing symptoms of nausea (OR=2.74) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluOverall tolerabilityNo significant difference
The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08-1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal distensionNo significant differenceRR=0.49, 95% CI: 0.33-0.72
abdominal distension (RR=0.49, 95% CI: 0.33-0.72)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal painNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication constipationNo significant differenceRR=0.38, 95% CI: 0.26-0.57
constipation (RR=0.38, 95% CI: 0.26-0.57)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diarrheaNo significant differenceRR=0.36, 95% CI: 0.26-0.48
reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66), diarrhea (RR=0.36, 95% CI: 0.26-0.48)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication nauseaNo significant differenceRR=0.50, 95% CI: 0.37-0.68
nausea (RR=0.50, 95% CI: 0.37-0.68)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication taste disordersNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication vomitingNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication